Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

112.99USD
4:00pm EDT
Change (% chg)

$-0.73 (-0.64%)
Prev Close
$113.72
Open
$114.11
Day's High
$114.18
Day's Low
$112.51
Volume
82,004
Avg. Vol
144,046
52-wk High
$177.74
52-wk Low
$96.76

Latest Key Developments (Source: Significant Developments)

Intercept Pharmaceuticals files for potential mixed shelf offering
Wednesday, 10 May 2017 06:12pm EDT 

May 10 (Reuters) - Intercept Pharmaceuticals Inc ::Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Intercept Pharmaceuticals Qtrly total revenue $21.0 mln
Thursday, 4 May 2017 07:05am EDT 

May 4 (Reuters) - Intercept Pharmaceuticals Inc ::Intercept Pharmaceuticals reports first quarter 2017 financial results and provides business update.Qtrly total revenue $ 21.0 million versus $ 445,000.Qtrly net loss per common and potential common share $ 3.61.Intercept pharmaceuticals - continues to project non-gaap adjusted operating expenses of $380 million to $420 million for fiscal year ending december 31, 2017.  Full Article

Intercept Pharmaceuticals reports Q4 sales $13.8 mln
Thursday, 23 Feb 2017 07:05am EST 

Intercept Pharmaceuticals Inc : Q4 sales $13.8 million . Intercept pharmaceuticals reports full year 2016 financial results and provides business update . Q4 revenue view $9 million -- Thomson Reuters I/B/E/S . Intercept pharmaceuticals inc sees NON-GAAP adjusted operating expenses of $380 million to $420 million for fiscal year ending december 31, 2017 .Qtrly loss per share $4.84.  Full Article

Intercept says European Commission grants Ocaliva marketing authorization
Wednesday, 14 Dec 2016 07:00am EST 

Intercept Pharmaceuticals Inc : European Commission grants Intercept's Ocaliva (obeticholic acid) marketing authorization for the treatment of primary biliary cholangitis .Intercept Pharmaceuticals-as conditions of approval, co required to provide post-approval updates on safety, efficacy analyses for Ocaliva.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 07:00am EDT 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Intercept Pharmaceuticals Q2 net loss per share $3.14
Thursday, 4 Aug 2016 07:05am EDT 

Intercept Pharmaceuticals Inc : Intercept pharmaceuticals reports second quarter 2016 financial results and provides business update . Net ocaliva 2q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenue . Q2 earnings per share view $-3.70, revenue view $1.5 million -- Thomson Reuters I/B/E/S . Qtrly net loss per share diluted $3.14 .Qtrly total revenue $5.5 million versus $445,000.  Full Article

Intercept Pharmaceuticals announces pricing of public offering
Thursday, 30 Jun 2016 09:18am EDT 

Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals announces pricing of public offering of convertible senior notes.  Full Article

Intercept Pharmaceuticals files for convertible senior notes for up to $400 mln
Wednesday, 29 Jun 2016 05:08pm EDT 

Intercept Pharmaceuticals Inc :Files for convertible senior notes for up to $400 million - SEC filing.  Full Article

Intercept Pharmaceuticals announces public offering of convertible senior notes
Wednesday, 29 Jun 2016 04:15pm EDT 

Intercept Pharmaceuticals Inc : Announces public offering of convertible senior notes . Says commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 .Says intends to use a portion of net proceeds from offering to fund payment of cost of capped call transactions.  Full Article

Intercept Pharmaceuticals Inc - FDA delays decision on lead drug - Reuters
Thursday, 17 Dec 2015 06:22pm EST 

Intercept Pharmaceuticals Inc:U.S. FDA postpones ruling on marketing application for Intercept's lead drug by three months to analyze additional clinical data - RTRS.  Full Article

More From Around the Web

BRIEF-Intercept Pharmaceuticals files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: (http://bit.ly/2r1bYv5) Further company coverage: